glp 1 drugs metformin Diabetic Agents, From to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar is glucophage a glp 1

Safety Considerations and Future Outlook As with all pharmacotherapy for obesity and T2D, establishing cardiovascular safety and demonstrating improvements in meaningful clinical outcomes will be essential, particularly as cardiovascular outcome trials have not yet been completed with multi-agonists (although data are expected soon for tirzepatide: SURPASS-CVOT [T2D] in 2025

Emphasis was placed on agonists that demonstrated positive predictions in terms of toxicity endpoints

Hybholt M

If you want to compare the two forms in more detail, Reduced vs

Disinfect the rubber stopper with an alcohol swab and allow it to dry completely